Chimeric Antigen Receptor (CAR) T-cell Therapy is a groundbreaking immunotherapy that involves genetically engineering a patient's T-cells to express receptors specifically targeting cancer cells, leading to their destruction. This personalized treatment has shown remarkable success in certain blood cancers, offering hope for patients with otherwise refractory diseases.